Here are three updates from gastroenterology companies from the past week:
Takeda's ulcerative colitis drug Entyvio was one of the key products behind a 4.2 percent increase in underlying revenue. Takeda reported 880.6 billion yen in revenue ($7.82 billion).
Cantel Medical Group appointed Bill Haydon as senior vice president and general manager of the company's medical division.
The Toronto Stock Exchange approved CRH Medical's intention to renew its normal course issuer bid.